NASDAQ · Biotechnology · USD
Disc Medicine, Inc. (IRON) Stock Analysis
Disc Medicine, Inc. (IRON) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
IRON Key Statistics
As of Oct 21, 2026Trading
- Open
- $77.80
- Previous Close
- $79.48
- Day's Range
- 75.89–81.50
- 52-Week Range
- 40.00–99.50
- Volume
- 4.60M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.11
Valuation
- Market Cap
- $2.92B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −6.58
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$212.18M
- Shares Outstanding
- 38.39M
- 1-Year Return
- −11.80%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 649.92K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, IRON closed at $76.00, −11.80% over 1 year.
Disc Medicine, Inc. (IRON) has a market capitalization of $2.92B.
In fiscal 2025, IRON reported revenue of $0.00.
IRON Stock Return by Calendar Year
Disc Medicine, Inc. (IRON) return since Aug 2020: what $10,000 became
- 1 year
- $10,000 $8,820
- −11.80%
- 5 years
- $10,000 $6,847
- −31.53%
- Since Aug 2020
- $10,000 $2,460
- −75.40%
If you had invested $10,000 in Disc Medicine, Inc. (IRON) at the close on August 12, 2020, the earliest close on record here, it would have been worth $2,460 at the close on October 21, 2026: −75.40% in total, −20.27% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −4.29% |
| 2025 | +25.25% |
| 2024 | +9.76% |
| 2023 | +190.40% |
| 2022 | −77.22% |
| 2021 | −73.55% |
| 2020 (partial year) | +6.80% |
As of October 21, 2026.
IRON Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$212.18M | — |
| 2024 | $0.00 | −$109.36M | — |
| 2023 | $0.00 | −$76.43M | — |
| 2022 | $0.00 | −$46.83M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$236.02M | −$212.18M | — |
| 2024 | $0.00 | — | −$129.72M | −$109.36M | — |
| 2023 | $0.00 | — | −$91.13M | −$76.43M | — |
| 2022 | $0.00 | — | −$47.48M | −$46.83M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
YahooWells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124
BenzingaWedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110
BenzingaDisc Medicine: APOLLO Changes The Story, But How Much Upside Remains
SeekingAlphaDisc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan
YahooAmazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Benzinga
All 20 articles ↓Show fewer ↑
Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus
YahooDisc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
YahooWhat Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?
YahooDisc’s once-spurned rare disease drug to get a second chance at approval
BioPharma DiveDisc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
MarketBeatDisc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
SeekingAlphaDisc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
YahooDisc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
Proactive InvestorsBMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120
BenzingaDisc Medicine Soars 35% as Rare Disease Drug Hits Every Phase 3 Endpoint: “A Potential Breakthrough”
TIKRDisc Medicine Shares Rise 60% After Phase 3 Bitopertin Trial Meets Primary and Secondary Endpoints
InvestorsHubDisc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
BenzingaPremarket Movers Oct. 19: Disc Medicine Jumps 51.62%, Rubico Falls 33.84%
ChartMillDisc Medicine surge 60% on positive Phase 3 trial for rare sunlight disorder
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B